Two Onc Docs ASCO GU 2025 Takeaways
Feb 18, 2025
The podcast dives into exciting findings from the ASCO GU conference, covering innovative treatments for kidney and bladder cancer. Key highlights include a pivotal triplet therapy trial for kidney cancer and breakthroughs in biomarkers like KIM-1. It discusses the transformative potential of N4-tamab combined with PEMBRO for bladder cancer treatment and insights on oncologists' treatment preferences. The effectiveness of talazoparib and enzalutamide in prostate cancer is also revealed, along with discussions on genetic factors and survival benefits.
Chapters
Transcript
Episode notes
1 2 3 4 5
Intro
00:00 • 2min
Exploring New Biomarkers and Patient Perspectives in Kidney Cancer
01:52 • 2min
Advancements in Bladder Cancer Treatment
03:32 • 5min
Survey Insights on Metastatic Bladder Cancer Treatment Preferences
08:21 • 2min
Insights on TALAPRO2 Trial and Future Implications for Prostate Cancer Treatment
09:59 • 3min